1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: Adverse events^{^a}
PRET-1 PRET-2 PRET
Platinum (n = 125) Hydrogel (n = 123) Platinum (n = 97) Hydrogel (n = 99) Platinum (n = 222) Hydrogel (n = 222)
Total 24 (19.2%) 26 (21.1%) 13 (13.4%) 15 (15.2%) 37 (16.7%) 41 (18.5%)
    SAH during follow-up 1 (0.8%) 0 (0.0%) 1 (1.0%) 2 (2.0%) 2 (0.9%) 2 (0.9%)
    Mass effect 0 (0.0%) 1 (0.8%) 2 (2.1%) 0 (0.0%) 2 (0.9%) 1 (0.5%)
    Stroke 1 (0.8%) 2 (1.6%) 1 (1.0%) 0 (0.0%) 2 (0.9%) 2 (0.9%)
    TIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.0%) 0 (0.0%) 1 (0.5%)
    Inflammatory 2 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.9%) 0 (0.0%)
    Subdural hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.0%) 0 (0.0%) 1 (0.5%)
    Non-neurologic 3 (2.4%) 1 (0.8%) 0 (0.0%) 0 (0.0%) 3 (1.4%) 1 (0.5%)
    Retreatment-related 1 (0.8%) 4 (3.3%) 2 (2.1%) 1 (1.0%) 3 (1.4%) 5 (2.3%)
    Periprocedural event 16 (12.8%) 18 (14.6%) 7 (7.2%) 10 (10.1%) 23 (10.4%) 28 (12.6%)
Serious 15 (12.0%) 15 (12.2%) 5 (5.2%) 10 (10.1%) 20 (9.0%) 25 (11.3%)
    Delayed 5 (4.0%) 7 (5.7%) 2 (2.1%) 4 (4.0%) 7 (3.2%) 11 (5.0%)
    Periprocedure 10 (8.0%) 8 (6.5%) 3 (3.1%) 6 (6.1%) 13 (5.9%) 14 (6.3%)
↵a Adverse events were recorded during the trial. Periprocedural events (within 1 month of procedure) are lumped together. Data are numbers.